United States: Plaintiff Attorney Advertising: Protected Or Prosecutable?

The barrage of plaintiff-attorney advertisements soliciting plaintiffs for drug and device litigation may spawn calls by executives, board members, and other company decision-makers to find out what can be done to stop them. Although certain categories of advertising are constitutionally protected as "free speech," developing precedent shows that attorney advertising may be susceptible to legal challenges under the Lanham Act. These claims have not been tested in court, but they present a legitimate possibility for manufacturers to mount an offensive attack against certain advertisements. This article provides an overview of the constitutional protections afforded attorney advertising in the United States, followed by an overview of new precedent under the Lanham Act and how it may be applied to combat certain advertising.

CONSTITUTIONAL PROTECTIONS FOR ATTORNEY ADVERTISING

Attorney advertising in the United States is well established as constitutionally protected commercial speech. In March 1975—when many state bar associations prohibited any form of attorney advertising—two lawyers in Arizona defied their state bar association's regulation prohibiting any form of attorney advertising and placed a newspaper ad that read: "DO YOU NEED A LAWYER? LEGAL SERVICES AT VERY REASONABLE FEES."1 When the Arizona State Bar suspended the lawyers for placing the ad, they challenged the disciplinary rule, paving the way for lawyer advertising to become protected free speech under the First Amendment.

The case, Bates v. State Bar of Arizona, reached the Supreme Court, which found outright bans on advertising like that imposed by the Arizona state bar to be unconstitutional.2 The Court specifically rejected the premise that advertising eroded "true professionalism" in the legal field, and determined instead that it was protected commercial speech.3 Bates was the end of absolute bans on attorney advertising.

It didn't take long for attorney advertising to develop into a vehicle for mass torts, starting in the 1980s with an attorney's advertisement in 36 Ohio newspapers soliciting women who used the Dalkon Shield Intrauterine Device.4 This advertisement contained a drawing of the device, asked the question "DID YOU USE THIS IUD?" and claimed that the device was "alleged to have caused serious pelvic infections resulting in hospitalizations, tubal damage, infertility, and hysterectomies."5 The ad offered legal representation, noting that "[i]f there is no recovery, no legal fees are owed by our clients."6 The Ohio Office of Disciplinary Counsel found such advertising was not sufficiently "dignified" or limited in scope to permissible information under its rules prohibiting illustrations and self-recommendation.7 It also found the ad violated a rule requiring that contingency-fee rates should disclose whether the percentages were computed before or after costs and expenses.8 The Supreme Court held that—except with regard to the misleading contingency fee statement—the advertisement's statements and illustration regarding the IUD were not false or misleading and were entitled to First Amendment protection.9

REGULATORY RESTRICTIONS ON ATTORNEY ADVERTISING

The American Bar Association's Model Rules of Professional Conduct ("Model Rules") serve as a standard for state bar associations, and each of the 50 states and the District of Columbia have adopted some variation of the Model Rules.10 The initial ethics rules, published in 1908, sought to compile a collection of norms for all attorney conduct.11 Solicitation by advertisement was deemed "unprofessional" and all forms of "self-laudation" were "intolerable," "defy[ing] the traditions and lower[ing] the tone of our high calling."12 Indeed, the best advertisement was "the establishment of a well-merited reputation for professional capacity and fidelity to trust."13

The ABA Model Rules published in 1983—after Bates—permitted attorney advertising through various publication modes, including television.14 The 1983 Model Rules also put specific limits on lawyers' direct solicitation of prospective clients and on lawyers' statements about certification fields of practice,15 but several Supreme Court rulings striking down state rules similar to the Model Rules spurred amendments.16 Further amendments resulted in the key prohibition on attorney advertising being limited to a showing that it is false or misleading speech.17 Under the Model Rules, an advertisement is "false or misleading if it contains a material misrepresentation of fact or law, or omits a fact necessary to make the statement considered as a whole not materially misleading."18 The result from the dilution of restrictions on advertising in the Model Rules following Bates is that most attorney advertising soliciting drug or device plaintiffs is permitted by state bar associations.

CHALLENGING FALSE OR MISLEADING ADVERTISING

Given the unlikelihood that state bar associations will pursue enforcement actions against attorney advertising, challenges by manufacturers must instead be made under common-law theories such as defamation and business torts or statutory claims under the Lanham Act. These claims focus not on statements about the lawyer or the lawyer's services, but on the content of the advertising that relates to a company's products and the impact of the advertisement on those products.

The most straightforward example of advertising that is "false or misleading" and susceptible to challenge is an ad that is obviously false. For example, an ad that claims a drug or medical device has been recalled by the FDA when in fact it has not is false and subject to immediate challenge. Such ads are usually addressed through cease-and-desist letters without the need for litigation.

Other examples of obvious falsity include misstatements about the product itself. For example, in 2011, Zimmer, Inc. sued Pulaski & Middleman, LLC—infamous for its "1-800-BADDRUG" ads—for "making false, misleading and defamatory statements about Zimmer and [its] NexGen® Knee System" in television advertisements.19 Zimmer alleged that the Pulaski Firm's ad was false or misleading by saying: "Reports show the ZIMMER NEXGEN KNEE IMPLANT MAY HAVE A FAILURE RATE OF 9%."20 Zimmer sued for defamation, tortious interference with business relationships, false advertising under the Lanham Act, product disparagement, and several trademark theories.21 The parties reached a confidential settlement, summarized by Zimmer in a public statement that the law firms "retracted the misleading claims in their advertisements" and that the firms would run corrective statements on their respective websites for six months. Zimmer's statement also indicated that the law firms either paid a monetary settlement, issued a retraction, or did both.22 Pulaski & Middleman's statement on its website admitted that it had "determined that the sources we previously relied upon to make claims about the Zimmer NexGen Knee System do not support the statements or implication" in the ads.23

While the Zimmer example is informative when an attorney advertisement obviously misstates factual information about a product, the more difficult question arises when an advertisement is not per se false, but is arguably misleading. Although claims for defamation and business torts remain options, recent precedent under the Lanham Act suggests that drug and medical-device manufacturers may have a better avenue to combat false or misleading advertising.

LANHAM ACT DEVELOPMENTS AND CHALLENGES TO ATTORNEY ADVERTISING

The Lanham Act provides a federal cause of action akin to unfair competition claims. The Act's provision regarding false advertising states:

(1) any person who, on or in connection with any goods or services . . . uses in commerce any word, term, name, symbol, or device, or any combination thereof, or any . . . false or misleading representation of fact which—

(B) in commercial advertising or promotion, misrepresents the nature, characteristics, qualities, or geographic origin of . . . another person's goods services or commercial activities,

shall be liable in a civil action by any person who believes that he or she is likely to be damaged by such act."24

Traditionally, a false-advertising claim under the Lanham Act arises when "one competito[r] directly injur[es] another by making false statements about his own goods [or the competitor's goods] thus inducing customers to switch."25 This underscores that any Lanham Act falseadvertising claim must be framed around economics—the manufacturer is losing business on the drug or device because of the defendant law firm's false advertising about that drug or device.

STANDING

The initial hurdle under the Lanham Act is standing to sue. Federal courts are prohibited from hearing cases in which the plaintiff has not "suffered or been imminently threatened with a concrete and particularized 'injury in fact'" that is traceable to the defendant's action.26 In 2014 the Supreme Court, in Lexmark International, Inc. v. Static Control Components, Inc., resolved a split in the Circuit Courts of Appeal as to the proper test for standing under the Lanham Act.27

Before Lexmark, a widely used limitation on Lanham Act claims was the "direct-competitor test," which required a plaintiff be in direct competition with the defendant in order to have standing. Under this test, a pharmaceutical or device manufacturer would not have standing to sue a law firm which would not be in competition with it. Lexmark rejected this approach, concluding that "a rule categorically prohibiting all suits by noncompetitors would read too much into the Act's reference to 'unfair competition.'"28 The Court noted that when the Lanham Act was adopted, noncompetitors could sue one another under the common law tort of unfair competition. Thus, it would be "a mistake to infer that because the Lanham Act treats false advertising as a form of unfair competition, it can protect only the false advertiser's direct competitors."29

The Lexmark Court determined that where a federal statute—like the Lanham Act—creates a cause of action, the plaintiff must fall within the "zone of interests" of that statute to have standing. To be "within the zone of interests in a suit for false advertising under [the Lanham Act], a plaintiff must allege an injury to a commercial interest in reputation or sales."30 Plaintiffs must also show that their injuries are proximately caused by violation of the statute. Therefore, a manufacturer would have to show "economic or reputational injury flowing directly from the deception wrought by the defendant's advertising; and that that occurs when deception of consumers causes them to withhold trade from the plaintiff."31

ELEMENTS OF A CLAIM

Assuming that the Supreme Court's ruling in Lexmark gives pharmaceutical and medical-device manufacturers standing to pursue a Lanham Act claim, they must still prove the elements of the claim itself. Generally, a plaintiff must prove "(1) the defendant has made false or misleading statements of fact concerning his own product or another's; (2) the statement actually or tends to deceive a substantial portion of the intended audience; (3) the statement is material in that it will likely influence the deceived consumer's purchasing decisions; (4) the advertisements were introduced into interstate commerce; and (5) there is some causal link between the challenged statements and harm to the plaintiff."32

First and foremost, the focus of the claim must be that losses are suffered because a false statement influenced a consumer's purchasing decision. The fact that the advertisements result in an increase in litigation is not relevant to any claim under the Lanham Act.

An actionable statement in an advertisement "must be based upon a statement of fact, not of opinion,"33 and a plaintiff must show that the advertisement "is literally false or that it is true yet misleading or confusing."34 If a statement is literally false, the plaintiff need not show actual deception of consumers; if a statement is literally true yet misleading, the plaintiff must show that consumers' decisions to purchase were actually influenced.35 Thus, the word "bad" next to "drug" in "1-800-BAD-DRUG" would be evaluated in context to determine whether it misleads consumers. Some courts apply a presumption of damages where the deception was willful, but this presumption only applies "to cases of comparative advertising where the plaintiff's product was specifically targeted."36 Therefore, a pharmaceutical manufacturer suing a noncompetitor law firm would likely have to present "evidence of the public's reaction through consumer surveys,"37 showing "that a significant portion of the consumer population was deceived."38 These proof requirements are not easily satisfied, and consumer surveys that satisfy the Lanham Act's requirements are both expensive and time consuming..

LIMITS

A pharmaceutical or device manufacturer will face two hurdles in bringing this type of Lanham Act claim. First, it must prove its standing to bring the claim— that it comes within the zone of interests of the statute. Although the Supreme Court's 2014 decision in Lexmark indicates that noncompetitors may bring claims under the Act, lower courts have not yet considered the standing of noncompetitors who are in different industries altogether. Second, pharmaceutical and device manufacturers must prove all of the elements of the Lanham Act claim itself, including deception of consumers and actual reliance.

CONCLUSION

The First Amendment's protection of commercial speech allows plaintiff law firms to solicit clients through advertisements that are not false or misleading, and states' rules of professional responsibility generally only prohibit false or misleading statements by an attorney. The Lanham Act and other common-law defamation causes of action may be available, but their proof requirements are strenuous. While the Supreme Court's Lexmark decision suggests that Lanham Act claims may be available against plaintiff law firms, those claims have not been tested. And, even if lower courts apply Lexmark to permit Lanham Act claims by manufacturers against plaintiff-firms, drug and device manufacturers still face an uphill battle in combating all but patently false advertisements.

Footnotes

1 Bates v. State Bar of Ariz., 433 U.S. 350, 385 (1977).

2 Id. at 383.

3 Id. at 368. As "commercial speech," attorney advertising became subject to a four part test for evaluating whether regulations limiting such speech are constitutional: (1) is the speech lawful and not misleading; (2) is the government interest in regulating the speech substantial; (3) does the regulation actually advance the government interest; and (4) if the interest could be achieved by a more limited restriction on commercial speech, the limitation fails.

4 Zauderer v. Office of Disciplinary Counsel of Supreme Court of Ohio, 471 U.S. 626, 630 (1985).

5 Id. at 631.

6 Id.

7 Id. at 632.

8 Id.

9 Id. at 641.

10 See Chronological List of States Adopting Model Rules, ABA, http://www.americanbar. org/groups/professional_responsibility/publications/model_rules_of_profession al_conduct/chrono_list_state_adopting_model_rules.html.

11 Colin Croft, Reconceptualizing American Legal Professionalism: A Proposal for Deliberative Moral Community, 67 N.Y.U. L. REV. 1256, 1306 (1992).

12 FINAL REPORT OF THE COMMITTEE ON CODE OF PROFESSIONAL ETHICS, Canon 27, available at http://www.americanbar.org/content/dam/aba/migrated/2011_build/professional_ responsibility/1908_canons_ethics.authcheckdam.pdf.

13 Id.

14 Model R. Prof. Conduct 7.2 (1983).

15 Model R. Prof. Conduct 7.3, 7.4 (1983).

16 See Shapero v. Ky. State Bar, 486 U.S. 466 (1988) (striking down Kentucky's rule regarding direct contact with prospective clients that was identical to the model rule); Peel v. Attorney Registration & Disciplinary Comm'n, 496 U.S. 91 (1990) (holding that states may not impose restrictions that burden a lawyer's truthful statement that he or she is a specialist, certified by an organization).

17 Model R. Prof. Conduct 7.1.

18 Id.

19 Complaint ¶¶ 53–58, Zimmer, Inc. v. Kresch/Oliver PLLC et al., No. 11CV00063, 2011 WL 767056 (N.D. Ind. Feb. 26, 2011); see also Erin Fuchs, Knee Device Maker Sues Plaintiffs Firm Over Ads, LAW360, http://www.law360.com/articles/284095/kneedevice-maker-sues-plaintiffs-firm-over-ads (Nov. 7, 2011).

20 Complaint, supra note 30, ¶ 54.

21 See id. ¶ 70–104.

22 Correcting the Record: Zimmer's Lawsuit, ZIMMERFACTS, http://zimmerfacts.com/background/index.html (last visited Jan. 29, 2016).

23 Alex Nussbaum & David Voreacos, Artificial-Knee Suits Targeting Zimmer Haunt Lawyers, BLOOMBERGBUSINESS, http://www.bloomberg.com/news/articles/2011-08-09/artificial-knee-suits-targeting- zimmer-haunt-lawyers-correct-(Aug. 9, 2011).

24 Lanham Act § 43(a), 60 Stat. 441, codified at 15 U.S.C. § 1125(a).

25 Lexmark Int'l, Inc. v. Static Control Components, Inc., 134 S. Ct. 1377, 1393 (2014) (internal quotation marks and citations omitted).

26 Id. at 1386 (citing Lujan v. Defenders of Wildlife, 504 U.S. 555, 560 (1992)).

27 134 S. Ct. 1377.

28 Id. at 1392 (citing 11 U.S.C. § 1127).

29 Id. at 1392.

30 Id. at 1390.

31 Id. at 1391.

32 Fed. Exp. Corp. v. United Parcel Serv., Inc., 765 F. Supp. 2d 1011, 1016–17 (W.D. Tenn. 2010) (quoting Am. Council of Certified Podiatric Physicians & Surgeons v. Am. Bd. of Podiatric Surgery, 185 F.3d 606, 613 (6th Cir. 1999).

33 Am. Council of Certified Podiatric Physicians & Surgeons, 185 F.3d at 614.

34 Id.

35 Id.

36 Balance Dynamics Corp. v. Schmitt Indus., Inc., 204 F.3d 683, 694 (6th Cir. 2000) (citing Porous Media Corp. v. Pall Corp., 110 F.3d 1329 (8th Cir. 1997)).

37 Id. at 616.

38 Id.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
 
In association with
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement

Mondaq.com (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of www.mondaq.com

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about Mondaq.com’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.

Disclaimer

Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.

Registration

Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to unsubscribe@mondaq.com with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.

Cookies

A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.

Links

This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.

Mail-A-Friend

If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.

Security

This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to webmaster@mondaq.com.

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to EditorialAdvisor@mondaq.com.

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at enquiries@mondaq.com.

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at problems@mondaq.com and we will use commercially reasonable efforts to determine and correct the problem promptly.